<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421005</url>
  </required_header>
  <id_info>
    <org_study_id>126/2004/U/Sper</org_study_id>
    <nct_id>NCT00421005</nct_id>
  </id_info>
  <brief_title>Fluvastatin After Heart Transplantation</brief_title>
  <official_title>Safety and Efficacy of Fluvastatin in Heart Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bologna</source>
  <brief_summary>
    <textblock>
      Statin therapy is a treatment with a proven positive impact on survival after heart
      transplantation. However, it is unclear whether the beneficial effect of this class of drugs
      depends solely on their LDL-lowering properties or on anti-inflammatory and immuno-modulatory
      properties. Thus, this study was designed to compare safety and efficacy of two different
      strategies: 1. high fixed statin dose vs. 2. low starting dose with LDL-driven doses
      adjustments.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2004</start_date>
  <completion_date type="Anticipated">November 2008</completion_date>
  <primary_completion_date type="Anticipated">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Heart Transplantation</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluvastatin 80mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluvastatin 20, tapered up according to LDL concentration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluvastatin</intervention_name>
    <description>Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Lescol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  De novo heart transplantation

        Exclusion Criteria:

          -  Known allergy/intolerance to fluvastatin;

          -  Preexisting neuromuscular disorders;

          -  Significant liver disease and/or elevation of transaminase exceeding 3 times the ULN

          -  Severe renal impairment : creatinine &gt; 3 mg/dL

          -  Intellectual/cognitive impairment likely to compromise informed consent or adherence
             to protocol or age &lt;18 years.

          -  Patients refusal

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelo Branzi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Alma Mater Studiorum University of Bologna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995 Sep 7;333(10):621-7.</citation>
    <PMID>7637722</PMID>
  </reference>
  <reference>
    <citation>Holdaas H, Fellström B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Grönhagen-Riska C, Neumayer HH, Maes B, Ambühl P, Hartmann A, Staffler B, Jardine AG; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005 Dec;5(12):2929-36. Erratum in: Am J Transplant. 2006 Aug;6(8):1986.</citation>
    <PMID>16303007</PMID>
  </reference>
  <reference>
    <citation>Grigioni F, Carigi S, Potena L, Fabbri F, Russo A, Musuraca AC, Coccolo F, Magnani G, Ortolani P, Leone O, Arpesella G, Magelli C, Branzi A. Long-term safety and effectiveness of statins for heart transplant recipients in routine clinical practice. Transplant Proc. 2006 Jun;38(5):1507-10.</citation>
    <PMID>16797344</PMID>
  </reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <last_update_submitted>April 28, 2009</last_update_submitted>
  <last_update_submitted_qc>April 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>University of Bologna</name_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

